Search Results - "Ottmann, O."

Clinical Pharmacokinetics of the BCR-ABL Tyrosine Kinase Inhibitor Nilotinib by Tanaka, C, Yin, O Q P, Sethuraman, V, Smith, T, Wang, X, Grouss, K, Kantarjian, H, Giles, F, Ottmann, O G, Galitz, L, Schran, H

“…This article describes studies that investigated the pharmacokinetics of nilotinib, a highly specific, oral, second‐generation BCR–ABL tyrosine kinase…”
Get full text

Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial) by Bug, G, Burchert, A, Wagner, E-M, Kröger, N, Berg, T, Güller, S, Metzelder, S K, Wolf, A, Hünecke, S, Bader, P, Schetelig, J, Serve, H, Ottmann, O G

Get full text

Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR–ABL1-positive acute lymphoblastic leukemia by Pfeifer, H, Wassmann, B, Bethge, W, Dengler, J, Bornhäuser, M, Stadler, M, Beelen, D, Vucinic, V, Burmeister, T, Stelljes, M, Faul, C, Dreger, P, Kiani, A, Schäfer-Eckart, K, Schwerdtfeger, R, Lange, E, Kubuschok, B, Horst, H A, Gramatzki, M, Brück, P, Serve, H, Hoelzer, D, Gökbuget, N, Ottmann, O G

“…Minimal residual disease (MRD) after allogeneic stem cell transplantation (SCT) for Ph+ acute lymphoblastic leukemia (ALL) is predictive of relapse. Imatinib…”
Get full text

Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study by Giles, F J, le Coutre, P D, Pinilla-Ibarz, J, Larson, R A, Gattermann, N, Ottmann, O G, Hochhaus, A, Radich, J P, Saglio, G, Hughes, T P, Martinelli, G, Kim, D-W, Novick, S, Gillis, K, Fan, X, Cortes, J, Baccarani, M, Kantarjian, H M

“…Nilotinib (Tasigna) is a BCR–ABL1 tyrosine kinase inhibitor approved for the treatment of patients with Philadelphia chromosome-positive chronic myeloid…”
Get full text

A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts by Garcia-Manero, G, Sekeres, M A, Egyed, M, Breccia, M, Graux, C, Cavenagh, J D, Salman, H, Illes, A, Fenaux, P, DeAngelo, D J, Stauder, R, Yee, K, Zhu, N, Lee, J-H, Valcarcel, D, MacWhannell, A, Borbenyi, Z, Gazi, L, Acharyya, S, Ide, S, Marker, M, Ottmann, O G

“…Treatment with azacitidine (AZA), a demethylating agent, prolonged overall survival (OS) vs conventional care in patients with higher-risk myelodysplastic…”
Get full text

Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1 by Pfeifer, H., Cazzaniga, G., van der Velden, V. H. J., Cayuela, J. M., Schäfer, B., Spinelli, O., Akiki, S., Avigad, S., Bendit, I., Borg, K., Cavé, H., Elia, L., Reshmi, S. C., Gerrard, G., Hayette, S., Hermanson, M., Juh, A., Jurcek, T., Chillón, M. C., Homburg, C., Martinelli, G., Kairisto, V., Lange, T., Lion, T., Mueller, M. C., Pane, F., Rai, L., Damm-Welk, C., Sacha, T., Schnittger, S., Touloumenidou, T., Valerhaugen, H., Vandenberghe, P., Zuna, J., Serve, H., Herrmann, E., Markovic, S., Dongen, J. J. M. van, Ottmann, O. G.

“…Minimal residual disease (MRD) is a powerful prognostic factor in acute lymphoblastic leukemia (ALL) and is used for patient stratification and treatment…”
Get full text

Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies by DeAngelo, D J, Spencer, A, Bhalla, K N, Prince, H M, Fischer, T, Kindler, T, Giles, F J, Scott, J W, Parker, K, Liu, A, Woo, M, Atadja, P, Mishra, K K, Ottmann, O G

“…Panobinostat is a potent oral pandeacetylase inhibitor that leads to acetylation of intracellular proteins, inhibits cellular proliferation and induces…”
Get full text

Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia by Pfeifer, H, Lange, T, Wystub, S, Wassmann, B, Maier, J, Binckebanck, A, Giagounidis, A, Stelljes, M, Schmalzing, M, Dührsen, U, Wunderle, L, Serve, H, Brück, P, Schmidt, A, Hoelzer, D, Ottmann, O G

“…Imatinib is highly effective in newly diagnosed, but not in relapsed, Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). BCR-ABL tyrosine…”
Get full text

A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors by Haense, N, Atmaca, A, Pauligk, C, Steinmetz, K, Marmé, F, Haag, G M, Rieger, M, Ottmann, O G, Ruf, P, Lindhofer, H, Al-Batran, S-E

“…Ertumaxomab (ertu) is a bispecific, trifunctional antibody targeting Her2/neu, CD3 and the Fcγ-receptors I, IIa, and III forming a tri-cell complex between…”
Get full text

Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase by Giles, F J, Kantarjian, H M, le Coutre, P D, Baccarani, M, Mahon, F-X, Blakesley, R E, Gallagher, N J, Gillis, K, Goldberg, S L, Larson, R A, Hochhaus, A, Ottmann, O G

“…Nilotinib is a selective inhibitor of BCR-ABL approved for use in newly diagnosed and imatinib-resistant or -intolerant patients with chronic myeloid leukemia…”
Get full text

UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia by SINGER, J. B, SHOU, Y, OTTMANN, O. G, GILES, F, KANTARJIAN, H. M, HSU, Y, ROBEVA, A. S, RAE, P, WEITZMAN, A, MEYER, J. M, DUGAN, M

“…Nilotinib is a novel BCR-ABL inhibitor with significantly improved potency and selectivity over imatinib. In Phase I and Phase II clinical studies of nilotinib…”
Get full text

A phase I trial of the trifunctional anti Her2 x anti CD3 antibody ertumaxomab in patients with advanced solid tumors by Haense, N, Atmaca, A, Pauligk, C, Steinmetz, K, Marmn, F, Haag, G. M, Rieger, M, Ottmann, O. G, Ruf, P, Lindhofer, H, Al-Batran, S.-E

Get full text

PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation by Mian, A A, Rafiei, A, Haberbosch, I, Zeifman, A, Titov, I, Stroylov, V, Metodieva, A, Stroganov, O, Novikov, F, Brill, B, Chilov, G, Hoelzer, D, Ottmann, O G, Ruthardt, M

“…Targeting BCR/ABL with tyrosine kinase inhibitors (TKIs) is a proven concept for the treatment of Philadelphia chromosome-positive (Ph+) leukemias. Resistance…”
Get full text

Correction: Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1 by Pfeifer, H., Cazzaniga, G., van der Velden, V. H. J., Cayuela, J. M., Schäfer, B., Spinelli, O., Akiki, S., Avigad, S., Bendit, I., Borg, K., Cavé, H., Elia, L., Reshmi, S. C., Gerrard, G., Hayette, S., Hermanson, M., Juh, A., Jurcek, T., Chillón, M. C., Homburg, C., Martinelli, G., Kairisto, V., Lange, T., Lion, T., Mueller, M. C., Pane, F., Rai, L., Damm-Welk, C., Sacha, T., Schnittger, S., Touloumenidou, T., Valerhaugen, H., Vandenberghe, P., Zuna, J., Serve, H., Herrmann, E., Markovic, S., van Dongen, J. J. M., Ottmann, O. G.

“…An amendment to this paper has been published and can be accessed via a link at the top of the paper…”
Get full text

Differential expression of miR-17∼92 identifies BCL2 as a therapeutic target in BCR-ABL-positive B-lineage acute lymphoblastic leukemia by Scherr, M, Elder, A, Battmer, K, Barzan, D, Bomken, S, Ricke-Hoch, M, Schröder, A, Venturini, L, Blair, H J, Vormoor, J, Ottmann, O, Ganser, A, Pich, A, Hilfiker-Kleiner, D, Heidenreich, O, Eder, M

“…Despite advances in allogeneic stem cell transplantation, BCR-ABL-positive acute lymphoblastic leukaemia (ALL) remains a high-risk disease, necessitating the…”
Get full text

The impact of COVID-19 on cancer care and oncology clinical research: an experts’ perspective by Sessa, C., Cortes, J., Conte, P., Cardoso, F., Choueiri, T., Dummer, R., Lorusso, P., Ottmann, O., Ryll, B., Mok, T., Tempero, M., Comis, S., Oliva, C., Peters, S., Tabernero, J.

“…The coronavirus disease-19 (COVID-19) pandemic promises to have lasting impacts on cancer clinical trials that could lead to faster patient access to new…”
Get full text

Differential expression of miR-17 similar to 92 identifies BCL2 as a therapeutic target in BCR-ABL-positive B-lineage acute lymphoblastic leukemia by Scherr, M, Elder, A, Battmer, K, Barzan, D, Bomken, S, Ricke-Hoch, M, Schroder, A, Venturini, L, Blair, H J, Vormoor, J, Ottmann, O, Ganser, A, Pich, A, Hilfiker-Kleiner, D, Heidenreich, O, Eder, M

“…Despite advances in allogeneic stem cell transplantation, BCR-ABL-positive acute lymphoblastic leukaemia (ALL) remains a high-risk disease, necessitating the…”
Get full text

SETBP1 mutation analysis in 944 patients with MDS and AML by Thol, F, Suchanek, K J, Koenecke, C, Stadler, M, Platzbecker, U, Thiede, C, Schroeder, T, Kobbe, G, Kade, S, Löffeld, P, Banihosseini, S, Bug, G, Ottmann, O, Hofmann, W-K, Krauter, J, Kröger, N, Ganser, A, Heuser, M

Get full text

Plastic CD34 and CD38 expression in adult B–cell precursor acute lymphoblastic leukemia explains ambiguity of leukemia-initiating stem cell populations by Lang, F, Wojcik, B, Bothur, S, Knecht, C, Falkenburg, J H F, Schroeder, T, Serve, H, Ottmann, O G, Rieger, M A

Get full text

MK-0457, an Aurora kinase and BCR–ABL inhibitor, is active in patients with BCR–ABL T315I leukemia by Giles, F J, Swords, R T, Nagler, A, Hochhaus, A, Ottmann, O G, Rizzieri, D A, Talpaz, M, Clark, J, Watson, P, Xiao, A, Zhao, B, Bergstrom, D, Le Coutre, P D, Freedman, S J, Cortes, J E

“…MK-0457, an Aurora kinase and BCR–ABL inhibitor, was studied on a Phase I/II study in 77 patients with refractory hematologic malignancies. The average number…”
Get full text